Worldwide, there’s an increasing trend of bacterial infections that are resistant to carbapenem antibiotics. In Asia and Singapore, these carbapenem-resistant bacterial infections (CR-GNB) lead to hundreds of avoidable deaths each year.
Currently, clinicians lack evidence to guide the best treatment choice for their patients, as well as tools to prevent infection spread. To bridge this healthcare gap, the Amritas team has been granted $10 million for a five-year project to find ways to fight superbugs or drug-resistant bacteria.
Hear from Professor Hsu Li Yang as he shares his expert opinion on CR-GNB and solutions that the Amritas team will be working on to address this.